Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.
暂无分享,去创建一个
M. Sorror | M. Maris | R. Storb | B. Sandmaier | D. Maloney | B. Storer | D. Niederwieser | P. Mcsweeney | M. Pulsipher | B. Bruno | J. Shizuru | G. Georges | T. Chauncey | E. Agura
[1] H. Goldschmidt,et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. , 2006, Blood.
[2] M. Maris,et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[4] H. Einsele,et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.
[5] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Kollman,et al. Outcome of unrelated transplants in patients with multiple myeloma , 2005, Bone Marrow Transplantation.
[7] M. Sorror,et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Barlogie,et al. Cure of myeloma: hype or reality? , 2005, Bone Marrow Transplantation.
[9] N. Kröger,et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] C. Flowers,et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.
[11] C. Flowers,et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.
[12] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[13] N. Russell,et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma , 2003, British journal of haematology.
[14] R. Storb,et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.
[15] S. Heimfeld,et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.
[16] M. Maris,et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.
[17] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[18] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[19] H. Einsele,et al. Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning , 2003, British journal of haematology.
[20] S. Mackinnon,et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] R. Storb,et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.
[22] G. Tricot,et al. Predicting Long-term Survival in Multiple Myeloma Patients Following Autotransplants , 2003, Leukemia & lymphoma.
[23] B. Barlogie,et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. , 2003, Experimental hematology.
[24] N. Schmitz,et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. , 2002, Blood.
[25] Robert A Kyle,et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Richard LeBlanc,et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.
[27] B. Barlogie,et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma , 2002, British journal of haematology.
[28] R. Bataille,et al. Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma , 2002, Leukemia.
[29] A. Anagnostopoulos,et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma , 2002, Bone Marrow Transplantation.
[30] N. Kröger,et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.
[31] B. Barlogie,et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Craddock,et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.
[33] B. Barlogie,et al. Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants , 2002, British journal of haematology.
[34] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[35] G. Gahrton,et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.
[36] P. Thall,et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.
[37] R. Fonseca,et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma , 1999, Bone Marrow Transplantation.
[38] Anajane G. Smith,et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.
[39] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[40] L. Schwartzberg,et al. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide, and granulocyte colony-stimulating factor with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. , 1998, American journal of clinical oncology.
[41] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] B. Barlogie,et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? , 1998, Bone Marrow Transplantation.
[43] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[44] S. Woo,et al. Graft-vs.-host disease. , 1997, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[45] R. Storb,et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.
[46] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[47] B. Barlogie,et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. , 1995, Bone marrow transplantation.
[48] B. Barlogie,et al. VAD‐based regimens as primary treatment for multiple myeloma , 1990, American journal of hematology.